News
Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...
Futurism on MSN33m
A Side Effect of Trump's Tariffs: Making Ozempic Way More Expensive
President Donald Trump's new European tariffs may spell bad news for Novo Nordisk, maker of Ozempic and Wegovy. As Axios ...
The Score is a weekly review of the biggest stock moves and the news that drove them. Whirlpool expects its performance to spin back around soon. The appliance maker on Monday cut its full-year profit ...
Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback